Munich/Martinsried (Germany), November 18, 2013. Coriolis Pharma (www.coriolis-pharma.com), a globally operating biopharmaceutical research and development service provider, organized a top-class scientific conference in Munich, Germany to mark its fifth anniversary. Around 130 participants had the opportunity to find out more about the latest scientific findings in formulation development and the stability of protein therapeutics. Prof. John Carpenter (University of Colorado) joined renowned international experts such as Prof. Wim Jiskoot (Leiden Academic Center for Drug Research), Prof. Gerhard Winter (Ludwig-Maximilian University, Munich), Prof. Wolfgang Friess (Ludwig-Maximilian University, Munich) and Prof. Christian Schoeneich (University of Kansas) at the conference.
As one of the keynote speakers at the 2013 Munich Protein Formulation and Stability Conference, Prof. John Carpenter explained to participants from the fields of science and industry how various biopharmaceutical manufacturing methods can influence the development of protein particles and how these processes can be monitored.
Protein Particles Cause Immunogenicity
Many suspect that such particle formation is one of the causes of immunogenicity reactions in patients following administration of biopharmaceuticals. Prof. Christian Schoeneich and Prof. Wim Jiskoot also took a look at this issue in their presentations. The renowned protein researchers all agreed that there is mounting evidence indicating that undesired protein particles can provoke immune responses in patients. Prof. Gerhard Winter gave participants insights into current trends in the freezedrying of biologics. His colleague Prof. Wolfgang Friess, also from the University of Munich’s Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, spoke about the aggregation of monoclonal antibodies. Dr. Andrea Hawe, Chief Scientific Officer of Coriolis Pharma, rounded out the program with an overview of established and emerging techniques for aggregate and particle characterization in biopharmaceuticals.
The service provider Coriolis Pharma organized the one-day conference on October 17 to mark its fifth anniversary. A specialized provider with high scientific standards, the independent privately owned company supports the biopharmaceutical industry in research and development projects in the fields of protein analysis and formulation development for biotechnological drugs.
Background: Coriolis Pharma
Coriolis Pharma is a globally operating independent service provider for formulation research and contract analysis of biopharmaceutical drugs (proteins, peptides, monoclonal antibodies and vaccines). Coriois Pharma provides formulation development and testing, pre-clinical material manufacturing, lyophilization processes, stability testing and innovative analytical services on behalf of pharmaceutical companies. The company is based in the German town of Martinsried, near Munich (www.coriolispharma. com).
Help employers find you! Check out all the jobs and post your resume.
